← Eichor
Study identifier: NCT05148286 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Albumin and Crystalloid Administration in Septic Shock

Condition: Septic Shock  ·  Sponsor: Asan Medical Center

PhasePhase 4
Planned participants2426
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The current guideline emphasizes fluid resuscitation as the mainstay of initial management for septic shock. Albumin has the oncotic activity to maintain intravascular volumes with additional beneficial properties in sepsis. Prior studies showed that the replacement of albumin might have survival advantages in patients with septic shock. The investigators aim to assess whether the early administration of albumin with crystalloid as initial fluid resuscitation improves survival in patients with septic shock compared to resuscitation without albumin.

This description comes directly from the study's public registry record.

Talk to the study team

Sang-Min Kim, Dr.  ·  82-10-3010-0730  ·  swdarkhorse@gmail.com

Won Young Kim, PhD  ·  wonpia73@naver.com

Always discuss trial participation with your own doctor first.

Locations (1)

Asan Medical CenterSeoul, South KoreaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05148286